DBV Technologies (NASDAQ:DBVT) Reaches New 12-Month Low – Here’s Why

DBV Technologies S.A. (NASDAQ:DBVT) reached a new 52-week low during trading on Friday. The company traded as low as $10.71 and last traded at $10.9550, with a volume of 80804 shares traded. The stock had previously closed at $11.21.

Analysts Set New Price Targets

Several equities analysts recently issued reports on DBVT shares. Wall Street Zen lowered DBV Technologies from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. HC Wainwright reaffirmed a “buy” rating on shares of DBV Technologies in a research note on Tuesday, June 30th. Citizens Jmp upped their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th. Weiss Ratings downgraded shares of DBV Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, July 17th. Finally, Citigroup reissued a “market outperform” rating on shares of DBV Technologies in a research report on Wednesday. Five investment analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $48.50.

DBV Technologies Stock Down 3.6%

The stock has a fifty day moving average of $13.31 and a 200-day moving average of $16.57. The firm has a market capitalization of $679.48 million, a P/E ratio of -3.08 and a beta of -1.04.

Institutional Inflows and Outflows

Several large investors have recently added to or reduced their stakes in DBVT. Perceptive Advisors LLC bought a new stake in DBV Technologies during the 1st quarter worth about $20,146,000. Vivo Capital LLC raised its holdings in DBV Technologies by 8.4% during the first quarter. Vivo Capital LLC now owns 2,667,569 shares of the company’s stock worth $55,726,000 after acquiring an additional 205,943 shares in the last quarter. ADAR1 Capital Management LLC bought a new position in DBV Technologies in the first quarter valued at approximately $21,159,000. Royal Bank of Canada grew its stake in DBV Technologies by 167.1% in the first quarter. Royal Bank of Canada now owns 4,680 shares of the company’s stock valued at $98,000 after purchasing an additional 2,928 shares in the last quarter. Finally, Elmind Capital LP acquired a new position in shares of DBV Technologies during the 1st quarter worth approximately $5,536,000. Institutional investors and hedge funds own 71.74% of the company’s stock.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company focused on developing treatments for food allergies and other immune-mediated conditions. The company’s lead technology, Viaskin, is designed to deliver targeted immunotherapy through the skin without requiring an injection. Its approach is intended to expose the immune system to controlled amounts of an allergen while limiting systemic exposure.

DBV Technologies’ primary product candidate is Viaskin Peanut, an investigational patch intended to treat peanut allergy, particularly in children.